DUBLIN--(BUSINESS WIRE)--The "Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 - 2025" report has been added to Research and Markets' offering.
The irritable bowel syndrome with diarrhea (IBS-D) drugs market was valued at USD 289.3 Mn in 2015, and is expected to reach USD 780.29 Mn by 2025, expanding at a CAGR of 13.89% from 2017 - 2025.
Recent approvals for two new prescription drugs to treat irritable bowel syndrome with diarrhea (IBS-D) have become the biggest phenomenon in the IBS-D drugs market. These approvals are viewed as breakthrough step in the long struggle to discover effective treatment for IBS-D.
Viberzi (eluxadoline) assists in controlling bowel contractions thus containing diarrhea, whereas Xifaxan (rifaximin) is an antibiotic that treats diarrhea by altering the gut flora. Xifaxan had been used off label for treating IBS-D, thus direct approval for treating IBS-D will lead to growth in demand for Xifaxan during the forecast period. Drugs such as loperamide will experience a slack in demand due to the introduction of the said novel drugs.
Commenting on the competitive scenario, the IBS-D drugs market is fragmented with no clear leader in terms of market revenue share. However, it is expected that with gradual approvals in the international markets, Valeant (Salix Pharmaceuticals) will emerge the market leader in the overall IBS drugs market with products for both IBS-D and IBS-C treatment.
Key Topics Covered:
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3 IBS-D Drugs Market: Market Dynamics and Outlook
Chapter 4 Global IBS-D Drugs Market Analysis, by Drugs
Chapter 5 Global IBS-D Drugs Market Analysis, By Prescription Type
Chapter 6 Global IBS-D Drugs Market Analysis, By Geography
Chapter 7 Company Profiles
- Astellas Pharmaceuticals
- Actavis
- Pfizer
- GlaxoSmithKline
- Salix Pharmaceuticals Ltd
- AstraZenenca
For more information about this report visit https://www.researchandmarkets.com/research/w4krht/global_irritable
